Eikon Therapeutics, Inc. (EIKN) stock
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$4.76−0.41 (-7.93%)
Close on Nov 19, 2026Market cap $257.83MP/E –Yield –
Eikon Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$65.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$90.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$76.88M | – |
See a number that looks wrong?